GlassScriptPhysician profile
Katherine Dadisman
NPI 1699748798
$2,634.39
in general payments reported to CMS, 2019-2025
32 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $192 · 2021: $387 · 2022: $301 · 2023: $415 · 2024: $383 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.36 |
| Education | $176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.47 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $364.07 | 2023-2025 | Veozah |
| Pfizer INC. | $284.98 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $154.84 | 2023-2025 | Myfembree, Gemtesa |
| Gynesonics, INC. | $143.88 | 2021 | |
| Coopersurgical, INC. | $97.59 | 2019-2025 | Supercut Hysterectomy Scissors, Summit Doppler, Paragard T 380a |
| Exact Sciences Corporation | $94.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $75.12 | 2019-2022 | |
| Millicent US INC | $68.70 | 2024-2025 | Intrarosa, Femring |
| Allergan, INC. | $66.96 | 2019 | |
| Aspira Women'S Health INC | $57.71 | 2022 | |
| Therapeuticsmd, INC. | $57.23 | 2019-2020 | |
| Organon LLC | $56.25 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $52.91 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $52.82 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $49.95 | 2020-2022 | |
| Agile Therapeutics, INC. | $48.49 | 2021-2023 | Twirla |
| Boston Scientific Corporation | $43.07 | 2023 | |
| Medtronic, INC. | $42.45 | 2025 | Truclear |
| Duchesnay USA Incorporated | $42.01 | 2019 | |
| Evofem Biosciences, INC. | $40.71 | 2022 | |
| Roche Diagnostics Corporation | $38.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.90 | 2019-2025 | |
| Amgen INC. | $35.16 | 2020 | |
| Agios Pharmaceuticals, INC. | $32.94 | 2025 | Pyrukynd |
| Sage Therapeutics, LLC | $28.95 | 2025 | Zurzuvae |
| Axonics, INC. | $23.68 | 2024 | Axonics, Bulkamid |
| Amag Pharmaceuticals, INC. | $23.27 | 2019-2020 | |
| Myovant Sciences INC. | $19.64 | 2021 | |
| Ascend Therapeutics US, LLC | $14.95 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.95 | 2019 | |
| Avion Pharmaceuticals | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Dadisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.